



Standardize Care for Your Patients With Overt Hepatic Encephalopathy (OHE)

Use the **XIFAXAN® Quick Support & Access Plugin and the Order Set Kit** to help standardize OHE care within your organization. Standardizing care within your workflow, helps you identify and manage your patients living with OHE.

The XIFAXAN QSA Plugin and Order Set Kit:

- Helps standardize OHE identification and management within the workflow
- Integrates provider, patient, and caregiver tools in one place
- Can be used in telehealth visits to make visits more impactful
- Helps patients get support and access to their prescribed treatment
- Assists with getting the organization to understand the benefits of creating an order set
- Provides the information you need for XIFAXAN prior authorizations

INDICATION

- XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

The XIFAXAN® Quick Support & Access Plugin

INDICATION
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults.

PROVIDER | CAREGIVER AND PATIENT | PRESCRIBING INFORMATION | IMPORTANT SAFETY INFORMATION

☐ Select tool(s) ☒ Preview tool ☒ Description

Provider

Resources

<input type="checkbox"/> PA Guide for Overt Hepatic Encephalopathy		✓
<input type="checkbox"/> Counseling Tips		✓
<input type="checkbox"/> Low-Income Subsidy Guide		✓
<input type="checkbox"/> Hepatic Encephalopathy Hospital Discharge Tips		✓

Fillable Forms

<input type="checkbox"/> Letter of Medical Necessity		✓
<input type="checkbox"/> Tier Exception Request		✓
<input type="checkbox"/> CoverMyMeds® ePA		✓

Identify a caregiver whenever possible who will help the patient with his or her treatment plan.

Caregiver and Patient

Resources

<input type="checkbox"/> XIFAXAN Instant Savings Card <small>PLEASE NOTE: This is an online form that allows you to download the card.</small>		✓
<input type="checkbox"/> Reduce the Risk of OHE Recurrence With XIFAXAN		✓
<input type="checkbox"/> Setting Up Medical Alerts on Digital Devices		✓

Video

<input type="checkbox"/> Managing Overt Hepatic Encephalopathy With XIFAXAN <small>PLEASE NOTE: This is a video. It cannot be printed.</small>		✓
---------------------------------------------------------------------------------------------------------------------------------------------------	--	---

Back to Top ↑

Email View/Print Copy Link

IMPORTANT SAFETY INFORMATION
• XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioedema, and anaphylaxis. Please click [here](#) for full Important Safety Information.

Salix

With the **XIFAXAN® Quick Support & Access Plugin**, you can integrate important forms and resources into your organization's workflow and have these resources at your fingertips.

Help Your Patients Get the Support and Access to Their Prescribed Treatment

Give your patients and their caregivers evidence-based tools and resources to help them:

- Provide guidance for how your patients can get support
- Understand OHE risks and treatment options
- Set up medical alerts on their digital devices

GINAT™ (Guided INtegrated Assistance) can help you integrate the plugin into your Epic EHR system.

GINA is a trademark of Aventria Health Group.

IMPORTANT SAFETY INFORMATION *(continued)*

- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.
- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Standardizing Care With an Order Set Kit

Standardizing care is clearer and more efficient when you have the proper order set appear in your EHR.² Additionally, standardizing care may help:

- ✓ Improve outcomes and reduce direct hospitalization costs*^{3,4,5}
- ✓ Integrate and coordinate care across multiple disciplines, levels of care, and services²
- ✓ Improve the efficiency of the workflow²
- ✓ Potentially reduce errors²

*Direct costs are based on initial admission, 30-day readmission, and one-year readmission direct costs of patients receiving a heart failure order set.

The OHE Order Set is based on evidence-based practice guidelines published by the American Association for the Study of Liver Diseases (AASLD; available at AASLD.org). Additionally, the Institute for Safe Medication Practices (ISMP) Guidelines for Standard Order Sets were used in the development of this order set.^{6,7}

The example order set can be used as a guide for educational purposes only. It is not intended to be a complete clinical representation for overt hepatic encephalopathy. Physicians should use their own clinical judgment in deciding what parts of the order set to incorporate and in diagnosing, counseling, and advising patients.

To order the **XIFAXAN® Quick Support & Access Plugin** and/or the OHE Order Set Kit, go to **xifaxansupport.com**.

IMPORTANT SAFETY INFORMATION *(continued)*

- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
- In a clinical study, the most common adverse reactions for XIFAXAN in HE ($\geq 10\%$) were peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%).

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Overt Hepatic Encephalopathy (OHE) Order Set Kit

OHE Order Set Kit Components

OHE Order Set Template provides an example of how to incorporate a standard order set and workflow into your organization's EHR system.


OHE Order Set Overview and Discussion Guide outlines the components of the OHE Order Set Kit and offers talking points to help establish the importance of the OHE Order Set.

OHE Order Set Training Presentation discusses the importance of the order set, how to get the order set, and nuances to be aware of when using it.

Policy Documents include relevant guidelines, prescribing information, and evidence-based studies used to create the resources in the OHE Order Set Kit.

Webinar Offer Email offers monthly webinars to assist in installation of the OHE Order Set Template within your EHR system.

Presentation Support Email offers support to answer health system questions about the value proposition deck, the rollout deck, or the training deck.



To order the **XIFAXAN® Quick Support & Access Plugin** and/or the OHE Order Set Kit, go to **xifaxansupport.com**.

IMPORTANT SAFETY INFORMATION (continued)

- INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

References: 1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*. 2014;60(2):715-735. 2. Ehringer G, Duffy B. Promoting best practice and safety through preprinted physician orders. In: Henriksen K, Battles JB, Keyes MA, et al, eds. *Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 2: Culture and Redesign)*. Rockville, MD: Agency for Healthcare Research and Quality; 2008. 3. Tapper EB, Finkelstein D, Mittleman MA. A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2016;14(5):753-759. 4. Ballard DJ, Ogola G, Fleming NS, et al. Impact of a standardized heart failure order set on mortality, readmission, and quality and costs of care. *Int J Qual Health Care*. 2010;22(6):437-444. 5. Ballard DJ, Ogola G, Fleming NS, et al. The impact of standardized order sets on quality and financial outcomes. In: Henriksen K, Battles JB, Keyes MA, et al, eds. *Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 2: Culture and Redesign)*. Rockville, MD: Agency for Healthcare Research and Quality; 2008. 6. American Association for the Study of Liver Diseases (AASLD). Practice guidelines. <https://www.aasld.org/publications/practice-guidelines>. Accessed May 7, 2020. 7. Institute for Safe Medication Practices (ISMP). Guidelines. <https://www.ismp.org/guidelines>. Accessed May 7, 2020.



Salix Pharmaceuticals: 400 Somerset Corporate Blvd., Bridgewater, NJ 08807
The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by
Alfasigma S.p.A. to Salix Pharmaceuticals or its affiliates.
© 2021 Salix Pharmaceuticals or its affiliates. XIF.0050.USA.20 V3.0

